(Q40568369)

21 September 2017

Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis (English)

1 reference

21 September 2017

1 reference

J Barth

1

1 reference

PubMed ID

23319088

21 September 2017

H Landen

series ordinal

2

1 reference

21 September 2017

1 January 2003

1 reference

Clinical Drug Investigation

21 September 2017

1 reference

21 September 2017

23

1 reference

21 September 2017

1

1 reference

21 September 2017

1-10

1 reference

Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study

21 September 2017

1 reference

12 December 2020

Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany

1 reference

12 December 2020

Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective

1 reference

12 December 2020

Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative

1 reference

12 December 2020

Infectious etiology of acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae

1 reference

12 December 2020

In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.

1 reference

12 December 2020

Quality of life in acute exacerbation of chronic bronchitis: results from a German population study.

1 reference

12 December 2020

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

1 reference

12 December 2020

Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.

1 reference

12 December 2020

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

1 reference

12 December 2020

Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients

1 reference

12 December 2020

Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults

1 reference

12 December 2020

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

1 reference

12 December 2020

The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience.

1 reference

12 December 2020

The role of bacteria in exacerbations of COPD. A constructive view

1 reference

12 December 2020

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

1 reference

12 December 2020

Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae

1 reference

12 December 2020

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

1 reference

12 December 2020

BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens

1 reference

12 December 2020

Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms

1 reference

12 December 2020

Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin

1 reference

12 December 2020

The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia

1 reference

12 December 2020

Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study

1 reference

12 December 2020

Improving care for patients with respiratory tract infections.

1 reference

12 December 2020

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

12 December 2020

A critical review of the fluoroquinolones: focus on respiratory infections

1 reference

12 December 2020

In vitro activity of Bay 12-8039, a new 8-methoxyquinolone

1 reference

12 December 2020

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society

1 reference

12 December 2020

Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin

1 reference

12 December 2020

Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study

1 reference

12 December 2020

Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis

1 reference

12 December 2020

Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756.

1 reference

12 December 2020

Susceptibility of penicillin-resistant and penicillin-susceptible Streptococcus pneumoniae to newer antimicrobial agents

1 reference

12 December 2020

Penetration of moxifloxacin into peripheral compartments in humans.

1 reference

12 December 2020

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

1 reference

12 December 2020

Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience

1 reference

12 December 2020

Do bacteria cause exacerbations of COPD?

1 reference

12 December 2020

A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis

1 reference

12 December 2020

The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.

1 reference

12 December 2020

10.2165/00044011-200323010-00001

Identifiers

DOI

1 reference

21 September 2017

1 reference

PubMed ID

23319088